预测静脉血栓栓塞症及血栓预防在转移性和复发性宫颈癌中的效用
该观察性队列研究纳入386例接受至少一线全身化疗的复发性或转移性宫颈癌患者,最终分析232例,其中89例(38%)发生静脉血栓栓塞症(VTE)。未发现BMI、Khorana评分、放疗、贝伐珠单抗或免疫治疗与VTE发生显著相关,无独立预测因素;作者认为因VTE发生率极高,可强烈考虑对复发性或转移性宫颈癌患者进行预防性抗凝。
要点
- 复发性或转移性宫颈癌患者VTE发生率为38%(89/232)。
- 未发现BMI、Khorana评分、放疗、贝伐珠单抗或免疫治疗与VTE发生显著相关。
- 作者认为因VTE发生率极高,可强烈考虑对复发性或转移性宫颈癌患者进行预防性抗凝。
核心结论
- 约40%的复发性或转移性宫颈癌患者发生新发VTE,未发现可预测VTE的独立危险因素。
- 作者认为因VTE发生率极高,可强烈考虑对复发性或转移性宫颈癌患者进行预防性抗凝。
研究设计与样本
- 观察性队列研究,纳入386例接受至少一线全身化疗的复发性或转移性宫颈癌患者,经纳入和排除标准筛选后232例纳入分析。
- 收集人口学、临床、组织学数据及Khorana评分,统计方法采用Pearson卡方检验、Student t检验和Wilcoxon秩和检验。
主要发现
- 232例患者平均年龄49岁(范围20-83岁),167例(72%)为鳞状细胞组织学。
- 169例(72.8%)因复发疾病接受治疗,63例(27.2%)因转移性IVB期疾病接受治疗。
- 180例(78%)既往接受放疗,134例(58%)接受贝伐珠单抗。
- 89例(38%)诊断为VTE,发生VTE与未发生VTE的患者在临床和病理特征上无统计学显著差异。
- BMI、Khorana评分、放疗、贝伐珠单抗或免疫治疗与VTE发生无显著关联。
临床怎么用
- 作者认为因VTE发生率极高,可强烈考虑对复发性或转移性宫颈癌患者进行预防性抗凝。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with cervical cancer who are diagnosed with venous thromboembolism (VTE) have worse outcomes compared to those not affected. There has yet to be a reliable method to predict or prevent VTE in cervical cancer patients. Our objective is to describe the incidence of VTE in patients with recurrent and metastatic (r/mCC) and determine risk factors that may predict VTE in this setting. METHODS: We performed an observational cohort study of 386 patients with r/mCC who received at least one line of systemic chemotherapy. We collected demographic, clinical, histologic data and Khorana scores for all patients. Inclusion and exclusion criteria were applied before analysis. Statistical analysis was performed using Pearson chi-square, Student's t-test, and Wilcoxon rank-sum. RESULTS: 232 patients were included for evaluation. Mean age was 49 years (range 20-83). The majority (167, 72%) of patients had squamous cell histology. 169 (72.8%) patients received treatment for recurrent disease and 63 (27.2%) for metastatic, stage IVB disease. 180 (78%) patients received prior radiation and 134 (58%) received bevacizumab. VTE was diagnosed in 89 (38%) patients. There were no statistically significant differences amongst clinical and pathologic characteristics between patients who developed VTE and those who did not. There was no significant association between BMI, Khorana score, radiation, bevacizumab, or immunotherapy and the development of VTE. CONCLUSION: Approximately 40% of patients with r/mCC experienced a new VTE. There were no independent risk factors that could predict VTE in this population. Due to the overwhelmingly high incidence of VTE, prophylactic anticoagulation could be strongly considered in patients with r/mCC.
引用
- Walker CA, Edwards C, McIntire D, et al. Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer. Gynecol Oncol. 2024. PMID: 38875744. doi:10.1016/j.ygyno.2024.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。